Similarly, tocilizumab, that targets the interleukin-6 receptor and is approved for RA, reduced kidney damage by preventing ferroptosis through increased levels of GPX4, xCT, and ferritin (Yang et al. 2020). The gene discussed is IL6R; the disease is rheumatoid arthritis.